secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2021-12-30T23:59:59+00:00
Accession:  0001558370-21-017078
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties
--------------------------------------------------------------------------------

- Received ~$126M cash at closing; retains accounts receivable.
- Eligible for $200M milestone if separate OMIDRIA payment secured for 4 consecutive years before 2025.
- US royalty: 50% of net sales until milestone/2025, then 30% through patent life (2032).
- Ex-US royalty: 15% of net sales on country-by-country basis.
- Transaction removes OMIDRIA revenue and costs from continuing ops; pro forma shows ongoing R&D and SG&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021017078/0001558370-21-017078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021017078/omer-20211223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-017078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer